Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the voluntary withdrawal of the supplemental Biologics License Application (sBLA) for Libtayo® (cemiplimab-rwlc) as a second-line treatment for patients with advanced cervical cancer. The decision was made after the companies and the U.S. Food and Drug Administration (FDA) were not able to align on certain post-marketing studies. Discussions with regulatory authorities outside of the U.S. are ongoing.
https://finance.yahoo.com/news/regeneron-sanofi-regulatory-libtayo-cemiplimab-120000386.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.